Abstract Protein translation initiation is controlled by eukaryotic initiation factor 4E (eIF-4E) binding protein 1 (4E-BP1). Phosphorylated 4E-BP1 dissociates from eIF-4E, allowing translation of transcripts mediating cell cycling, survival, and angiogenesis. The expression and phosphorylation of 4E-BP1, and influence on prognosis of diffuse large B cell lymphoma (DLBCL), is unknown. Because at least some patients with low-risk (International Prognostic Index score 0-2) DLBCL treated with standard anthracycline-based chemotherapy experience a short survival, we examined if 4E-BP1 expression and phosphorylation may provide additional prognostic information in 35 patients with low-risk DLBCL. We examined their initial diagnostic pathology specimens for 4E-BP1 expression and phosphorylation using immunohistochemistry, and we correlated these with clinical outcomes. While 4E-BP1 was uniformly expressed, there was wide distribution in its level of phosphorylation (biological activity). 4E-BP1 phosphorylation correlated strongly with overall survival (OS; P=0.007) and progression-free survival (PFS; P=0.02) and was the most significant independent variable for both OS and PFS on multivariable analysis. Our findings suggest that immunohistochemical evaluation of 4E-BP1 phosphorylation may help refine the prognostication of patients with low-risk DLBCL. Prospective studies in an independent cohort of patients are warranted.
Introduction
There has been considerable interest in identifying molecular mechanisms that contribute to the pathogenesis and clinical behavior of lymphomas in order to refine prognostication and select patients who may benefit from novel targeted therapies. Diffuse large B cell lymphoma (DLBCL) is an excellent example since it is clinically heterogeneous, and multiple efforts are ongoing to identify prognostic factors that help recognize patients who might need more aggressive or targeted first-line treatment [1] .
Several cell signaling pathways have been discovered in the past decade with important clinical implications. Protein translation initiation appears to be tightly regulated by eukaryotic initiation factor 4E (eIF-4E; Fig. 1 ), which binds the 5′ cap end of mRNA and mediates cap-dependent translation [2, 3] . eIF-4E binding protein 1 (4E-BP1) regulates the function of eIF-4E by binding to eIF-4E in the nonphosphorylated form. Phosphorylation of 4E-BP1 (p4E-BP1) dissociates the molecule from eIF-4E, thereby allowing translation of several cap-dependent transcripts responsible for cell cycling, survival, and angiogenesis, including c-myc, cyclin D1, ornithine decarboxylase, survivin, bcl-2, vascular endothelial growth factor, fibroblast growth factor 2, matrix metalloproteinase 9, and heparinase [4] . Our group reported that transfection of solid tumor cells with wild-type 4E-BP1 or the constitutively active mutant 4E-BP1 A37/A46 represses tumorigenicity and augments apoptosis following chemotherapy [5, 6] .
eIF-4E expression itself is elevated in several carcinomas and hematopoietic malignancies, and this has been shown to correlate with disease progression and survival [7] . Furthermore, expression and phosphorylation of 4E-BP1 correlate with histological grade and clinical behavior of diverse malignancies [4, 8, 9] . Since many signaling pathways converge on 4E-BP1, this has been termed a "funnel factor" [4] , therapeutic targeting of which may be effective in many malignancies including lymphomas [10] [11] [12] [13] [14] .
eIF-4E is involved in the pathogenesis of murine lymphoma [15] and influences the behavior of lymphomas in humans [16] [17] [18] [19] [20] . Less is known about the expression of its regulatory protein 4E-BP1 in lymphomas. Others reported that 4E-BP1 is expressed in MCL [21, 22] . We recently reported that 4E-BP1 is widely expressed in most subtypes of B cell lymphomas, that the level of phosphorylation (indicative of activity) of 4E-BP1 varies widely among the different subgroups, and that in low-grade lymphomas, the expression of phosphorylated 4E-BP1 parallels the expression of bcl-2 [23] .
In the present study, we examined the expression and phosphorylation of 4E-BP1 in diagnostic samples from a cohort of patients with low-risk DLBCL and evaluated if this correlated with clinical features at diagnosis or with outcomes following first-line anthracycline-based chemotherapy.
Patients and methods

Patients
We identified 35 patients diagnosed with low-risk DLBCL (International Prognostic Index (IPI) score 0-2) at the Minneapolis VA Medical Center (MVAMC) from 1993 to 2006, for whom adequate original diagnostic tissue material and follow-up clinical data were available. Data pertaining to the diagnosis, treatment, response, and survival were obtained by retrospective chart review. The study was approved by the institutional Human Subjects Committee.
Immunohistochemical analysis
Formalin-fixed paraffin-embedded diagnostic tissues were retrieved from the archives of the Department of Pathology at the MVAMC. Tissues were stained for bcl-2 using a mouse monoclonal antibody (clone E17, Cell Marque, Rocklin, CA) at 1:50 dilution with EDTA-based antigen retrieval, total 4E-BP1 and phosphorylated 4E-BP1 (p4E-BP1 [Thr37/46]) using rabbit monoclonal anti-4E-BP1 (clone 53H11; Cell Signaling Technology, Danvers, MA) at 1:3,000 dilution and with citrate-based antigen retrieval, and rabbit monoclonal anti-p4E-BP1 (clone 236B4, Cell Signaling Technology) at 1:100 dilution and with EDTA-based antigen retrieval respectively, on a Bondmax automated immunostainer (Leica Biosystems, Bannockburn, IL) as previously described by us [23] . The slides were read by two hematopathologists (A.R. and H.M.) blinded to the clinical data and were analyzed for percentage of cells positive (scale, 0 to 100) and intensity of cytoplasmic and/or nuclear expression (0, 1+, 2+, or 3+, denoting none, weak, moderate, and strong staining, respectively). An expression score was calculated from their product ([% cells positive×intensity]/10), thus ranging from 0 to 30, similar to previous reports [8] . A score of 0-15 was considered to be low, and a score of 16-30 was considered to be high.
Statistical analysis
Differences between groups were compared using a two-tailed t test. In patients who received chemotherapy, the probabilities of overall survival (OS) and progression-free survival (PFS) were determined using the Kaplan-Meier method. The effects of the level of phosphorylation of 4E-BP1, IPI score, and age and use of rituximab on OS and PFS were estimated using the Cox proportional hazards regression model (SPSS software, version 19.0). Survival graphs were generated using GraphPad Prism 5.0 (GraphPad Software Inc., San Diego, CA, USA).
Results
Clinical data
The median age was 68 years (range, 25-91); 71 % of patients were >60 years. All but one of the patients were male, a reflection of the patient population at a VA hospital. Consistent with their low IPI scores, the majority (77 %) of patients had early stage (stage I or II) disease at diagnosis (Table 1 ). All patients had received cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)-based chemotherapy with (n=15) or without (n=20) rituximab. Patients who had not received CHOP-based chemotherapy were not included in this analysis.
4E-BP1 expression and phosphorylation
Most cases examined expressed total 4E-BP1 uniformly (97 % samples; data not shown). However, there was wide distribution in the level of phosphorylation of 4E-BP1 (low However, the level of phosphorylation of 4E-BP1 correlated strongly with overall survival (Fig. 3a) . The OS was significantly better (P=0.007) in patients with low levels of phosphorylation of 4E-BP1 (expression score=0-15; n=17) compared to those with higher levels of 4E-BP1 phosphorylation (expression score=16-30; n=18). The median survival was 146 vs 21 months, and the 5-year survival was 82 vs 32 %, in patients with low and high levels of 4E-BP1 phosphorylation, respectively. Similarly, the level of phosphorylation of 4E-BP1 (low vs high) correlated significantly with progression-free survival (P=0.02; Fig. 3b) . The median PFS was 128 vs 20 months, and the 5-year survival was 71 vs 32 %, in patients with low and high levels of 4E-BP1 phosphorylation, respectively. The difference in survival between the two groups was not a consequence of differences in age or IPI score at diagnosis. As shown in Table 3 , the level of phosphorylation of 4E-BP1 was the most impactful of these factors on both univariable and multivariable analyses for OS and PFS.
Discussion
DLBCL is a clinically heterogeneous malignancy, with marked variability in response to chemotherapy and longterm survival. Several studies have identified molecular subtypes of DLBCL with significantly different survival following anthracycline-based therapy (reviewed by Ninan et al. [1] ).
The level of expression and phosphorylation of 4E-BP1 varies widely in different malignancies [4, 8, 9] . In accordance with these observations, we report that the extent of phosphorylation of 4E-BP1 varies considerably in DLBCL. A high level of expression of phosphorylated 4E-BP1 in neoplastic lymphocytes would be expected to upregulate cap-mediated translation of proteins responsible for angiogenesis, and malignant cell proliferation and survival [4, 9, 10, 17, 18, 20, 24, 25] . The inferior survival associated with increased expression of phosphorylated 4E-BP1 that we report. DLBCL is consistent with these phenomena, and in keeping with previous reports in other malignancies including malignant melanoma and cancers of the breast, ovary, prostate and stomach [26] [27] [28] . In the present study, we limited the analysis to patients with low-risk DLBCL, in order to examine if differences in p4E-BP1 expression may help explain at least some of the known variability in outcomes of patients who are otherwise believed to have a good prognosis.
Several drugs, including ribavirin (that interferes with eIF-4E-mediated translation via interference with cap binding) and agents that inhibit the mammalian target of rapamycin (mTOR) pathway upstream of eIF-4E are already available for clinical use and have shown some therapeutic activity in myeloid and lymphoid malignancies [12, 13] . In addition, specific antisense oligonucleotides [10] and small molecules [29] that interfere with the interaction of eIF-4E and the cap structure and thereby interrupt translation [30] are under development and in early clinical trials. The investigational agent enzastaurin (in phase III trials in DLBCL) inhibits PKC and PI3K/AKT signaling upstream of the eIF-4E pathway, inducing apoptosis of malignant cells via hypophosphorylation of 4E-BP1 [31] .
Our finding that the level of phosphorylation of 4E-BP1 provides independent prognostic information in low-risk DLBCL indicates that there is a need for confirmation in a larger, prospective study where all patients are treated with R-CHOP chemotherapy. Whether the level of phosphorylation of 4E-BP1 influences the prognosis of patients with high risk DLBCL also needs to be examined prospectively. Immunohistochemical assessment of phosphorylation of 4E-BP1 might then advance to clinical use in helping to refine the prognostication of a subset of patients diagnosed with DLBCL. Furthermore, if the influence of phosphorylated 4E-BP1 on the clinical behavior of DLBCL is confirmed, it will provide the rationale for trials to evaluate if incorporation of targeted agents that inhibit the eIF-4E pathway into therapeutic regimens might improve the survival of DLBCL patients, particularly those with lower IPI scores and high levels of 4E-BP1 phosphorylation. 
